118 related articles for article (PubMed ID: 16118017)
1. A delivery strategy for rotenone microspheres in an animal model of Parkinson's disease.
Huang J; Liu H; Gu W; Yan Z; Xu Z; Yang Y; Zhu X; Li Y
Biomaterials; 2006 Feb; 27(6):937-46. PubMed ID: 16118017
[TBL] [Abstract][Full Text] [Related]
2. Role of L-thyroxin in counteracting rotenone induced neurotoxicity in rats.
Salama M; Helmy B; El-Gamal M; Reda A; Ellaithy A; Tantawy D; Mohamed M; El-Gamal A; Sheashaa H; Sobh M
Environ Toxicol Pharmacol; 2013 Mar; 35(2):270-7. PubMed ID: 23357603
[TBL] [Abstract][Full Text] [Related]
3. An effective novel delivery strategy of rasagiline for Parkinson's disease.
Fernández M; Negro S; Slowing K; Fernández-Carballido A; Barcia E
Int J Pharm; 2011 Oct; 419(1-2):271-80. PubMed ID: 21807080
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration study.
Zhang ZN; Zhang JS; Xiang J; Yu ZH; Zhang W; Cai M; Li XT; Wu T; Li WW; Cai DF
Brain Res; 2017 Jan; 1655():104-113. PubMed ID: 27876560
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
[TBL] [Abstract][Full Text] [Related]
6. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of rotenone-induced dopaminergic cell death in the striatum by oxytocin treatment.
Erbaş O; Oltulu F; Taşkiran D
Peptides; 2012 Dec; 38(2):312-7. PubMed ID: 22985856
[TBL] [Abstract][Full Text] [Related]
8. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.
Caboni P; Sherer TB; Zhang N; Taylor G; Na HM; Greenamyre JT; Casida JE
Chem Res Toxicol; 2004 Nov; 17(11):1540-8. PubMed ID: 15540952
[TBL] [Abstract][Full Text] [Related]
9. [Effect of electroacupuncture stimulation of "Fengfu" (GV 16) and "Taichong" (LR 3) on expression of COX-2 and tyrosine hydroxylase in Substantia Nigra in rats with Parkinson's disease].
Wang SJ; Fang JQ; Ma J; Zhou D; Wang YC; Gan SY; Sun GJ
Zhen Ci Yan Jiu; 2013 Jun; 38(3):198-201. PubMed ID: 24006664
[TBL] [Abstract][Full Text] [Related]
10. Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease.
Garbayo E; Montero-Menei CN; Ansorena E; Lanciego JL; Aymerich MS; Blanco-Prieto MJ
J Control Release; 2009 Apr; 135(2):119-26. PubMed ID: 19154763
[TBL] [Abstract][Full Text] [Related]
11. Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.
Liu Y; Sun JD; Song LK; Li J; Chu SF; Yuan YH; Chen NH
Behav Brain Res; 2015 Nov; 294():149-61. PubMed ID: 26239001
[TBL] [Abstract][Full Text] [Related]
12. Investigation of tyrosine hydroxylase and BDNF in a low-dose rotenone model of Parkinson's disease.
Johnson ME; Lim Y; Senthilkumaran M; Zhou XF; Bobrovskaya L
J Chem Neuroanat; 2015 Dec; 70():33-41. PubMed ID: 26562783
[TBL] [Abstract][Full Text] [Related]
13. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
[TBL] [Abstract][Full Text] [Related]
14. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
15. Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease.
Badawi GA; Abd El Fattah MA; Zaki HF; El Sayed MI
Inflammopharmacology; 2017 Jun; 25(3):369-382. PubMed ID: 28258522
[TBL] [Abstract][Full Text] [Related]
16. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
Saravanan KS; Sindhu KM; Mohanakumar KP
Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
[TBL] [Abstract][Full Text] [Related]
17. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
Testa CM; Sherer TB; Greenamyre JT
Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
[TBL] [Abstract][Full Text] [Related]
18. Colonic electrical stimulation improves colonic transit in rotenone-induced Parkinson's disease model through affecting enteric neurons.
Bu J; Qiao X; He Y; Liu J
Life Sci; 2019 Aug; 231():116581. PubMed ID: 31220524
[TBL] [Abstract][Full Text] [Related]
19. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
Neuroscience; 2012 Feb; 203():170-9. PubMed ID: 22198020
[TBL] [Abstract][Full Text] [Related]
20. The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings.
von Wrangel C; Schwabe K; John N; Krauss JK; Alam M
Behav Brain Res; 2015 Feb; 279():52-61. PubMed ID: 25446762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
